Page 37 - Read Online
P. 37

Toscano et al. Neuroimmunol Neuroinflammation 2021;8:14-41  I  http://dx.doi.org/10.20517/2347-8659.2020.12  Page 33

               18.  Andersson M, Alvarez-Cermeño J, Bernardi G, Cogato I, Fredman P, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a
                   consensus report. J Neurol Neurosurg Psychiatry 1994;57:897-902.
               19.  Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, et al. Recommended standard of cerebrospinal fluid analysis
                   in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-70.
               20.  Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald
                   criteria. Lancet Neurol 2018;17:162-73.
               21.  Schwenkenbecher P, Wurster U, Konen FF, Gingele S, Sühs KW, et al. Impact of the McDonald criteria 2017 on early diagnosis of
                   relapsing-remitting multiple sclerosis. Front Neurol 2019;10:188.
               22.  Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. New diagnostic criteria for multiple sclerosis: guidelines for research
                   protocols. Ann Neurol 1983;13:227-31.
               23.  McDonald WI, Compston A, Edan G, Goodkin D, Hartung P, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines
                   from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
               24.  Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald
                   Criteria.” Ann Neurol 2005;58:840-6.
               25.  Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the
                   McDonald criteria. Ann Neurol 2011;69:292-302.
               26.  Sandberg-Wollheim M, Olsson T. Cerebrospinal fluid oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably
                   downplayed by the McDonald criteria 2010: Yes. Mult Scler 2013;19:714-6.
               27.  Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.
                   Brain 2018;141:1075-84.
               28.  Tintoré M, Rovira A, Brieva L, Grivé E, Jardí R, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and
                   different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359-63.
               29.  Tintoré M, Rovira A, Río J, Tur C, Pelayo R, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?
                   Neurology 2008;70:1079-83.
               30.  Boyko A. Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group. Mult
                   Scler 2020;26:869-70.
               31.  Makhani N, Lebrun C, Siva A, Narula S, Wassmer E, et al; Observatoire Francophone de la Sclérose en Plaques (OFSEP), Société
                   Francophone de la Sclérose en Plaques (SFSEP), the Radiologically Isolated Syndrome Consortium (RISC) and the Pediatric
                   Radiologically Isolated Syndrome Consortium (PARIS). Oligoclonal bands increase the specificity of MRI criteria to predict multiple
                   sclerosis in children with radiologically isolated syndrome. Mult Scler J Exp Transl Clin 2019;5:2055217319836664.
               32.  Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, et al. Neurofilament light chain and oligoclonal bands are
                   prognostic biomarkers in radiologically isolated syndrome. Brain 2018;141:1085-93.
               33.  Pryce G, Baker D. Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity
                   matter? Mult Scler Relat Disord 2018;25:131-7.
               34.  Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients:
                   10-year observational study. Mult Scler Relat Disord 2019;27:117-20.
               35.  Mancuso R, Franciotta D, Rovaris M, Caputo D, Sala A, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of
                   multiple sclerosis patients: a longitudinal study. Mult Scler 2014;20:1900-3.
               36.  von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, et al. Disappearance of cerebrospinal fluid oligoclonal bands after
                   natalizumab treatment of multiple sclerosis patients. Mult Scler 2012;18:1038-41.
               37.  Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active
                   disease during natalizumab therapy. Mult Scler 2013;19:1209-12.
               38.  Koch M, Heersema D, Mostert J, Teelken A, De Keyser J. Cerebrospinal fluid oligoclonal bands and progression of disability in multiple
                   sclerosis. Eur J Neurol 2007;14:797-800.
               39.  Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central
                   nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401.
               40.  Mayringer I, Timeltaler B, Deisenhammer F. Correlation between the IgG index, oligoclonal bands in CSF, and the diagnosis of
                   demyelinating diseases. Eur J Neurol 2005;12:527-30.
               41.  Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J
                   Neuroimmunol 2006;180:17-28.
               42.  Lefvert AK, Link H. IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol 1985;17:13-20.
               43.  Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, et al. Cerebrospinal fluid immunoglobulin kappa light chain in clinically
                   isolated syndrome and multiple sclerosis. PLoS One 2014;9:e88680.
               44.  Izquierdo G, Angulo S, Garcia-Moreno JM, Gamero MA, Navarro G, et al. Intrathecal IgG synthesis: marker of progression in multiple
                   sclerosis patients. Acta Neurol Scand 2002;105:158-63.
               45.  Klein A, Selter RC, Hapfelmeier A, Berthele A, Müller-Myhsok B, et al. CSF parameters associated with early MRI activity in patients
                   with MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e573.
               46.  Gastaldi M, Zardini E, Franciotta D. An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. Expert
                   Rev Mol Diagn 2017;17:31-46.
               47.  Hegen H, Walde J, Milosavljevic D, Aboulenein-Djamshidian F, Senel M, et al. Free light chains in the cerebrospinal fluid. Comparison
   32   33   34   35   36   37   38   39   40   41   42